Veraxa Biotech AG
VRXAWNASDAQHealthcareBiotechnology
Previous close
$0.0999
+$0.0187 · +23.03%
Aug 21, 4:00 PM ET
VRXAW company overview
Regular session · ET · Market data may be delayed.
Company profile
Company websiteVeraxa Biotech AG is a clinical-stage biopharmaceutical company specializing in next-generation antibody-based cancer therapies. [9] The company is advancing a drug discovery and development engine for ADCs and other novel antibody-based therapy concepts. [14] It was founded on scientific breakthroughs made at the European Molecular Biology Laboratory (EMBL). [8, 14]
- Industry
- Biotechnology
- Sector
- Healthcare
- Headquarters
- DE
- CEO
- Christoph Antz
- Listed since
- Jun 10, 2026
- Employees
- 47
Market position
- Open
- $0.0999
- Previous close
- $0.0812
- Volume
- 852
- 0.01× average
- Average volume
- 64.84K
- Average daily volume
- Market cap
- 2.53M USD
- Beta
- 0.54
- Market reference 1
- 50-day average
- $0.1321
- -24.38% below average
- 200-day average
- $0.1361
- -26.59% below average
VRXAW peers
Continue in GoAI
Research VRXAWresearch.disclaimer